Revolution Medicines, Inc.: Carcinoma, Non-Small-Cell Lung trials

The registry lists 11 Carcinoma, Non-Small-Cell Lung studies with Revolution Medicines, Inc. as lead sponsor. 8 are open to participants now and 2 have results posted.

Phase 1 8Phase 2 6Phase 3 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLCRecruitingNCT07777822Phase 3
• Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid TumorsRecruitingNCT07397338Phase 1/2
• Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid TumorsRecruitingNCT07349537Phase 1
• Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)RecruitingNCT06881784Phase 3
• Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingNCT06162221Phase 1/2
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRecruitingNCT06128551Phase 1/2
• Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid TumorsRecruitingNCT06040541Phase 1
• Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RASRecruitingNCT05379985Phase 1/2
• Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesCompletedNCT05054725Phase 2Results posted
• Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCCompletedNCT03989115Phase 1/2Results posted
• Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsActive, not recruitingNCT05462717Phase 1